The company has significantly improved its financial stability by reducing the debt-to-equity ratio from 3.26 in 2024Q4 to 0.03 in 2026Q1.
| Total Current Assets | 1.15B | 831.14M | 661.64M | 483.54M | 544.55M | 552.86M | 264.68M | 127.35M |
| Cash & Short-Term Investments | 705.58M | 577.94M | 470.65M | 318.82M | 409.55M | 466.6M | 207.31M | 86.48M |
| Cash Only | 705.58M | 577.94M | 432.86M | 202.9M | 409.55M | 466.6M | 207.31M | 86.48M |
| Short-Term Investments | 0 | 0 | 37.79M | 115.91M | 0 | 0 | 0 | 0 |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 162.1M | 0 | 37.08M | 44.97M | 42.11M | 0 | 0 | 0 |
| Total Non-Current Assets | 116.24M | 234.64M | 120.42M | 108.34M | 89.32M | 78.04M | 73.83M | 66.09M |
| Property, Plant & Equipment | 70.94M | 71.27M | 74.96M | 61.86M | 42.99M | 38.21M | 37.03M | 27.44M |
| Fixed Asset Turnover | 57.98x | 55.41x | 36.07x | 29.48x | 33.36x | 30.56x | 25.90x | 27.58x |
| Goodwill | 32.06M | 32.06M | 34.83M | 34.83M | 34.81M | 29.3M | 29.3M | 29.3M |
| Intangible Assets | 4.55M | 4.55M | 4.55M | 5.25M | 5.48M | 5.81M | 5.34M | 5.67M |
| Long-Term Investments | 28.41M | 28.41M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | - | - | - | - | - | - | - | - |
| Total Assets | 1.26B | 1.07B | 782.06M | 591.88M | 633.86M | 630.89M | 338.5M | 193.44M |
| Asset Turnover | 3.84x | 3.70x | 3.46x | 3.08x | 2.26x | 1.85x | 2.83x | 3.91x |
| Asset Growth % | 176.05% | 36.28% | 32.13% | -6.62% | 0.47% | 86.38% | 74.99% | - |
| Total Current Liabilities | 724.76M | 476.53M | 351.85M | 263.02M | 229.96M | 167.25M | 153.45M | 130.26M |
| Accounts Payable | 0 | 474.57M | 242.5M | 170.07M | 171.92M | 17.43M | 128.28M | 117.73M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 1.96M | 1.21M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | - | - | - | - | - | - | - |
| Other Current Liabilities | 724.76M | 0 | 38.72M | 34.11M | 0 | 0 | 0 | 0 |
| Current Ratio | 1.58x | 1.74x | 1.88x | 1.84x | 2.37x | 3.31x | 1.72x | 0.98x |
| Quick Ratio | 1.58x | 1.74x | 1.88x | 1.84x | 2.37x | 3.31x | 1.72x | 0.98x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 329.97M | 409.98M | 329.26M | 170.79M | 164.6M | 157.59M | 154.44M | 141.9M |
| Long-Term Debt | 6.35M | 323.18M | 321.43M | 161.81M | 160.9M | 150.62M | 144.17M | 137.96M |
| Capital Lease Obligations | 0 | - | - | - | - | - | - | - |
| Deferred Tax Liabilities | 0 | - | - | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - | - | - | - |
| Total Liabilities | 1.05B | 886.51M | 681.11M | 433.81M | 394.56M | 324.84M | 307.89M | 272.15M |
| Total Debt | 6.35M | 338.07M | 329.26M | 170.79M | 164.6M | 157.59M | 154.44M | 137.96M |
| Net Debt | -699.23M | -239.87M | -103.6M | -32.12M | -244.95M | -309M | -52.87M | 51.47M |
| Debt / Equity | 0.03x | 1.89x | 3.26x | 1.08x | 0.69x | 0.51x | 5.05x | - |
| Debt / EBITDA | 0.10x | 7.47x | - | - | - | - | 15.14x | - |
| Net Debt / EBITDA | -10.54x | -5.30x | - | - | - | - | -5.18x | - |
| Interest Coverage | 1.27x | 0.94x | -4.44x | -5.98x | -7.16x | -10.20x | -0.35x | -2.00x |
| Total Equity | 206.88M | 179.28M | 100.95M | 158.07M | 239.3M | 306.06M | 30.61M | -78.71M |
| Equity Growth % | 220.34% | 77.58% | -36.13% | -33.95% | -21.81% | 899.82% | 138.89% | - |
| Book Value per Share | 0.97 | 0.91 | 0.53 | 0.85 | 1.32 | 1.78 | 0.16 | -0.52 |
| Total Shareholders' Equity | 206.88M | 179.28M | 99.85M | 156.95M | 238.13M | 306.04M | 30.61M | -78.71M |
| Common Stock | 207K | 205K | 192K | 189K | 187K | 187K | 164K | 0 |
| Retained Earnings | -997.6M | -1.01B | -1.01B | -880.26M | -732.24M | -582.69M | -379.57M | -78.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 1.1M | 1.13M | 1.18M | 15K | 0 | 0 |
Regulatory reimbursement rate volatility
As reported in recent financial statements, Alignment Healthcare has grown total assets to $1.3 billion in 2026Q1, a significant increase from $591.9 million in 2023Q4, signaling that the company is successfully scaling its operational footprint despite the persistent pressure of accumulated deficits on the equity base.
The rapid expansion of the asset base suggests a deliberate strategy to capture market share in the Medicare Advantage space, though this growth is heavily reliant on external capital and operational scaling. Investors should monitor whether this asset accumulation translates into sustainable long-term returns or if it merely reflects the high capital intensity required to enter new geographic markets.
Based on the latest quarterly figures, the company's debt-to-equity ratio has compressed to 0.03 in 2026Q1 from a peak of 3.26 in 2024Q4, indicating a significant reduction in financial leverage that may provide the firm with greater flexibility to navigate potential regulatory headwinds in the coming periods.
The dramatic reduction in debt levels suggests that management is prioritizing a cleaner balance sheet to mitigate interest rate sensitivity and financial risk. This shift appears to be a strategic move to improve the company's risk profile as it approaches a potential inflection point in its path toward consistent profitability.
According to the balance sheet data, Alignment Healthcare has significantly bolstered its liquidity position, with cash and equivalents rising to $705.6 million in 2026Q1, providing a substantial buffer against the inherent volatility of medical claims payments and the potential for unexpected shifts in CMS reimbursement rates.
The current ratio of 1.58 suggests that the company maintains sufficient short-term assets to cover its immediate obligations, which is critical given the unpredictable nature of medical loss ratios. This liquidity position appears to be a defensive necessity, ensuring the firm can sustain operations through periods of high claims activity without requiring emergency external financing.
As indicated by the company's financial filings, the equity base remains constrained by a persistent accumulated deficit of $997.6 million as of 2026Q1, which highlights the ongoing challenge of achieving sustained profitability while simultaneously funding aggressive growth and high levels of stock-based compensation.
The negative retained earnings balance underscores the company's status as a growth-stage entity that has yet to achieve the scale necessary to offset its historical operating losses. Investors should interpret this as a signal that the company's equity value is currently driven more by future growth expectations than by the accumulation of earned capital.
Quick answers to the most common questions about buying ALHC stock.
As of 2025, Alignment Healthcare, Inc. (ALHC) had total assets of $1.07B including $831.1M in current assets.
Alignment Healthcare, Inc. (ALHC) carries total debt of $338.1M, offset by $577.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Alignment Healthcare, Inc. (ALHC) has total shareholders' equity (book value) of $179.3M ($0.91 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Alignment Healthcare, Inc. (ALHC) reported a current ratio of 1.74x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.